Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their upcoming webinar titled "A Lipid Nanoparticle Quantitative Systems Pharmacology (QSP) Case Study". The webinar airs live Wednesday, September 12, 2018 at 2p.m. ET / 11a.m. PT.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced their participation at the 9th annual World Bispecific Summit occurring September 19-20, 2018 in Boston, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced an extension to their collaboration with Northern Biologics Inc. to include Phase I clinical analyses for MSC-1, their lead antibody therapeutic targeting the cytokine LIF for the treatment of cancer.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk and accelerate drug research and development, today announced a collaboration with Revitope for an in-vitro and human mechanistic PK/PD modeling of Revitope's bispecific T Cell Engaging Antibody Circuits (TEAC) targeting solid tumors. "TEAC are designed to increase tumor specificity and launch an immune activation only when bound to the cancer cell surface.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Sanofi for the analysis of systems pharmacology pharmacokinetic (PK)/target engagement (TE) models for bispecific antibody combinations. Applied BioMath will help assess the risk and feasibility of multispecific combinations and compare them to fixed dose combinations (FDC) for multiple targets. These analyses will be used to help prioritize the portfolio and provide early screening criteria for lead generation.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Sanofi to develop quantitative systems pharmacology (QSP) models in immuno-oncology. Applied BioMath will leverage its proprietary modeling platform to develop QSP pharmacokinetic (PK) and pharmacodynamics (PD) models for multiple therapeutics in both animal and human species.
Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that CytomX has once again chosen Applied BioMath for the development of their semi-mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) models of human for immuno-oncology. "Our choice of Applied BioMath for continued QSP model development reflects a track record of past successes with high-quality, innovative, and timely deliverables.
[Webinar] Quantitative Modeling and Simulation Approaches: Driving Critical Decisions from Research through Clinical Trials
November 7, 2017 | 1 pm to 2 pm ET
Hosted by: Cambridge Healthtech Institute
Applied BioMath, the industry-leader in applying mechanistic modeling to drug research and development, today announced that they have been awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the annual Drug Development Boot Camp November 15-16, 2017 at the Harvard Club in Boston, MA. The Drug Development Boot Camp is hosted by Speid & Associates, Inc., in coordination with Harvard’s Office of Technology Development, and is a two-day intensive program for executive-level individuals that involves hands-on learning about the drug development process.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic systems modeling, simulation, and analysis to de-risk drug research and development, today announces their upcoming participation at PEGS: The Essential Protein Engineering Summit being held April 30 - May 4, 2018 in Boston, MA. Applied BioMath is sponsoring, exhibiting, presenting a poster, and presenting two talks at the conference.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic mathematical modeling, simulation, and analysis to de-risk therapeutic research and development, today announced a collaboration with Checkpoint Therapeutics, Inc., for semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling in advanced metastatic solid tumors.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to de-risk drug research and development, today announced a collaboration with Xencor to perform semi-mechanistic PK/PD modeling to analyze Xencor's XmAb® IL15/IL15Rα-Fc program for the treatment of solid tumors. The collaboration will focus on developing a mathematical model relating XmAb®24306 modulated potency and extended half-life to observed pharmacokinetics and in vivo T-cell stimulation.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to accelerate and de-risk drug research and development, today announced a collaboration with Pandion Therapeutics for semi-mechanistic pharmacokinetic and target occupancy (PK/TO) modeling in Autoimmune Disease.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling, simulation, and analysis to drug research and development, today announced their newest Science Advisory Board member, Dhaval K. Shah, PhD.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Compass Therapeutics for the semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling of a therapeutic targeting solid tumors. Semi-mechanistic PK/PD models will be developed for mouse, cynomolgus monkey, and human species and will help answer strategic questions such as the target coverage required for efficacy and dose regimen selection for the clinical study.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the annual Drug Development Boot Camp November 15-16, 2017 at the Harvard Club in Boston, MA. The Drug Development Boot Camp is hosted by Speid & Associates, Inc., in coordination with Harvard's Office of Technology Development, and is a two-day intensive program for executive-level individuals that involves hands-on learning about the drug development process.
Applied BioMath® (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at PepTalk: The Protein Science Week being held January 8-12, 2018 in San Diego, California.
Applied BioMath® (www.appliedbiomath.com), the industry leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Syntimmune to provide semi-mechanistic pharmacokinetic and pharmacodynamic (PK/PD) modeling for Syntimmune's ongoing clinical trials. Applied BioMath will deploy its Model-Aided Drug Invention (MADI) to analyze clinical data from Syntimmune's lead drug candidate, SYNT001.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced that Dr. Douglas A. Lauffenburger has joined the speaker lineup for QSP Day 2018. The conference occurs Thursday, April 12, 2018 from 9:00 a.m. - 5:00 p.m. at the Samberg Conference Center, MIT Chang Building in Cambridge, MA.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation at the Antibody Engineering and Therapeutics Conference December 11-15, 2017 in San Diego, CA. John Burke, PhD, will present Model Aided Drug Invention (MADI) case studies on Thursday, December 14, 2017 at 12:00 p.m. In addition to speaking at the event, Applied BioMath is also participating as a scientific briefing sponsor.
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in FierceBiotech’s second Drug Development Forum occurring September 25-27, 2017 in Boston, MA. Applied BioMath will be a sponsor as well as presenter at the event.
In this interview with CEOCFO Magazine, Dr. John M. Burke, Co-founder, President and CEO at Applied BioMath discusses how Applied BioMath is modernizing drug discovery, drug development, and clinical trials by applying quantitative systems pharmacology (QSP), mathematical modeling and machine learning techniques to drug research and development. "We help predict the failures much earlier - with the killer experiment, to help reduce late stage attrition rates," said Dr. John Burke. "This helps our collaborators prioritize their resources and their experiments."
Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced their participation in the upcoming American Conference on Pharmacometrics (ACoP) occurring October 15-18, 2017 in Fort Lauderdale, FL. Applied BioMath will be a conference sponsor, exhibitor, and poster presenter. Applied BioMath’s posters will highlight several examples of model-aided drug invention (MADI) by presenting case studies in immuno-oncology, osteoarthritis, and antibody-drug conjugates. More specifically, they will show: